Arca
Skip to content
Tools
Tools

CD44: CD44 antigen

Cell-surface receptor that plays a role in cell-cell interactions, cell adhesion and migration, helping them to sense and respond to changes in the tissue microenvironment.

  • Drugs that act on it: 3
  • Approved: 0
  • In phases 1 to 3: 2
  • Sponsors: 1

Who is on it, and how far along

Every drug ChEMBL records acting on CD44, by the furthest stage it has reached for any use, coloured by modality.

How to read this

Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.

  • Antibody 1
  • Antibody-drug conjugate 1
  • Other 1

Approved0

    Phase 30

      Phase 21

      • Bivatuzumab

      Phase 11

      • Bivatuzumab mertansine

      Preclinical or unknown1

      • PF-03475952

      The landscape

      Every drug acting on it, furthest along first. The sponsor is the US application holder where there is one, else the industry lead sponsor of most of its registered trials.
      BivatuzumabPhase 2Boehringer Ingelheim PharmaceuticalsAntibodyBinding agentCD44 antigen binding agent0
      Bivatuzumab mertansinePhase 1—Antibody-drug conjugateBinding agentCD44 antigen binding agent0
      PF-03475952Preclinical or unknown—OtherInhibitorCD44 antigen inhibitor0

      Diseases most associated with it

      Open Targets association score, 0 to 1; all associations
      • Nephrolithiasis, calcium oxalate0.52
      • Calcium oxalate urolithiasis0.52
      • Uterine corpus leiomyoma0.48
      • Thyroiditis0.28
      • Hypothyroidism0.26
      • Hashimoto thyroiditis0.26
      • Liver disorder0.25
      • Thyroid gland disorder0.22
      • Neurodegenerative disease0.20

      Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL3232692, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-21. Gene name, function (UniProt P16070, CC BY 4.0) and disease associations are from Open Targets (CC0). ChEMBL and Open Targets

      Esc

      Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

      Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.